Compare AbbVie Inc (ABBV) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $31.43 with a modest 0.67% daily gain. Technical indicators show a bearish bias overall, with moving averages signaling caution, though oscillators are neutral. The ETF, which provides 3x leveraged exposure to long-duration U.S. Treasuries, faces significant volatility due to its daily leverage reset mechanism. Recent news highlights its high-risk nature, with one article noting a substantial decline from a $10,000 investment five years ago to approximately $1,527, underscoring the perils of long-term holding.

The outlook for TMF is highly speculative and tied to interest rate movements. While some see opportunity at perceived lows in the bond market, the consensus warns it is unsuitable for long-term investment. Primary risks include extreme volatility from daily leverage resets and adverse shifts in Treasury yields. It remains a tactical, short-term instrument for experienced traders, not a core portfolio holding.